Company: CMND
Filing Date: 2025-11-26
Form Type: 424B5
Source: 0001213900-25-115106
Chunk: 9

Company: Clearmind Medicine Inc.
Filing Date: 2025-11-26
Form: 424B5
Chunk 9
---
First November 2025 Registered Direct Offering

On November 13, 2025, we entered into a definitive securities purchase agreement with investors for the purchase and sale of (i) 958,222 common shares, and (ii) pre-funded warrants to purchase up to 2,984,146 common shares, in a registered direct offering, or the November 2025 Offering, at a purchase price of $0.20 per common share and $0.1999 per pre-funded warrant.

The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire until exercised in full.

The November 2025 Offering closed on November 13, 2025. The aggregate gross proceeds to the Company were approximately $0.788 million.

Second November 2025 Registered Direct Offering

On November 17, 2025, we entered into a definitive securities purchase agreement with investors for the purchase and sale of (i) 3,991,768 common shares, and (ii) pre-funded warrants to purchase up to 1,518,000 common shares, in a registered direct offering, or the Second November 2025 Offering, at a purchase price of $0.25 per common share and $0.2499 per pre-funded warrant.

The pre-funded warrants are immediately exercisable at an exercise price of $0.0001 per common share, subject to adjustment as set forth therein, and will not expire until exercised in full.

The Second November 2025 Offering closed on November 17, 2025. The aggregate gross proceeds to the Company were approximately $1.377 million.

<div align='center'>S-3</div>

Third November 2025 Registered Direct Offering

On November 19, 2025, we entered into a definitive securities purchase agreement with investors for the purchase and sale of 10,925,000 common shares, at a purchase price of $0.20 per common share

The Third November 2025 Offering closed on November 20, 2025. The aggregate gross proceeds to the Company were approximately $2.185 million.

Warrant Exercises

As of November 25, 2025, investors from our financings in April 2023 and January 2024 exercised an aggregate of warrants to purchase 2,894,769 common shares, including warrants to purchase 1,881,250 common shares on a cashless basis. As a result,